No Signs of the DOJ Letting Off the Pedal with Medicare Fraud Investigations
However, a new memo instructs federal prosecutors to ‘avoid overreach’ when parties cooperate with authorities
Author Information
Scott Wallask
Scott Wallask is senior editorial manager at G2 Intelligence and its sibling brands, The Dark Report, Today’s Clinical Lab, Lab Manager, and Lab Design News. During his 30-year career, he has covered the clinical lab, healthcare, and high-tech markets during stints at TechTarget, HCPro, ZoomInfo, and the SAPinsider family of online publications. A former newspaper reporter, he graduated from Northeastern University with a bachelor’s degree in journalism. He can be reached at swallask@clinicallab.com.
Posts by the Author
CLIA-lcaEnforcement-lcaEnforcement-lirEnforcement-nirEssentialFDA-lirFDA-nirLab Industry AdvisorLDTs-lirScott Wallask
LDT Appeal: Looking at the Legal Nuances Behind Potential FDA Actions Following Court Decision
Marginal LDT scenarios could be where the FDA focuses on next, a lawyer notes
CLIA-nirCMS-nirCompliance-nirEnforcement-nirEssentialFDA-lcaFDA-lirFDA-nirLab Industry AdvisorLDTs-lirScott Wallask
LDT Oversight Remains Under CLIA, for Now
Judge rules that the FDA has ‘no authority’ to issue its rule governing laboratory-developed tests
XiFin’s Payor Rate Transparency Monitor Helps Clinical Labs Compare In-Network Rates
The free online tool can set a foundation for renewed reimbursement strategies and contract negotiations with insurance carriers
Six Sigma Can Help Monitor New CLIA Proficiency Testing Changes
A PT update went into effect on January 1, focusing on revised acceptance limits, among other modifications
How the LDT Final Rule’s Exemptions Apply to Oncology Labs
Regulatory expert explores whether any exclusions might benefit cancer laboratories trying to navigate upcoming compliance deadlines
‘Full Speed Ahead’ with Test Results? Not So Fast
Lab scientists using testing equipment too quickly brings up training concerns in discussions at recent ADLM conference
Expert Q&A: Labs Must Take a Greater Role in Guiding Clinicians About Abnormal Data
Lee Fleisher, MD, advocates for clearer interpretation of test results by medical laboratory scientists
Special Report: The 2024 Lab Enforcement Landscape
Lab leaders should be wary of telemedicine arrangements, certain marketing firms, and unnecessary PGx and CGx testing
Special Analysis: Addressing Key Concerns Around the FDA’s Final LDTs Rule
Experts answer key questions related to laboratory-developed test regulation during G2 Intelligence webinar.
